| Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
Verve Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 6, 2024 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders considered and voted on the four proposals set forth below, each of which is described in greater detail in the Company’s definitive proxy statement, filed with the U.S. Securities and Exchange Commission on April 26, 2024. The final voting results are set forth below.
Proposal 1 – Election of Class III Directors
The stockholders of the Company elected Burt Adelman and Sekar Kathiresan to serve as Class III directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2027 and until each of their successors has been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class III directors were as follows:
|
|
|
|
|
|
|
| |
|
Votes
For |
|
Votes
Withheld |
|
Broker
Non-Votes |
| Burt Adelman, M.D. |
|
27,760,743 |
|
17,141,076 |
|
24,032,475 |
| Sekar Kathiresan, M.D. |
|
44,455,131 |
|
448,061 |
|
24,031,102 |
Proposal 2 – Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm
The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the stockholders’ vote with respect to such ratification were as follows:
|
|
|
|
|
|
|
| Votes
For |
|
Votes
Against |
|
Votes Abstaining |
|
Broker Non-Votes |
| 68,752,292 |
|
76,802 |
|
105,200 |
|
0 |
Proposal 3 – Approval, on an Advisory Basis, of Compensation Paid to Company’s Named Executive Officers
The stockholders of the Company approved, on an advisory basis, the compensation paid to its named executive officers. The results of the stockholders’ non-binding, advisory vote with respect to compensation paid to the Company’s named executive officers were as follows:
|
|
|
|
|
|
|
| Votes
For |
|
Votes
Against |
|
Votes Abstaining |
|
Broker Non-Votes |
| 39,396,050 |
|
5,481,524 |
|
25,644 |
|
24,031,076 |
Proposal 4 – Approval, on an Advisory Basis, of the Frequency of Future Advisory Votes on the Compensation Paid to Company’s Named Executive Officers
The stockholders of the Company recommended, in a non-binding, advisory vote, that future advisory votes on the compensation of the Company’s named executive officers be held every year. The results of the stockholders’ non-binding, advisory vote with respect to the frequency of future advisory votes on the compensation paid to the Company’s named executive officers were as follows:
|
|
|
|
|
|
|
|
|
| Every 1 Year |
|
Every 2 Years |
|
Every 3 Years |
|
Votes Abstaining |
|
Broker Non-Votes |
| 44,065,864 |
|
446,673 |
|
349,187 |
|
41,495 |
|
24,031,075 |
No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.